Innovation Delivered: Resco Launches Autumn Update at resco.next 2019 Keynote
Resco, the leading provider of enterprise mobility solutions for Microsoft Dynamics 365 and Salesforce, has today officially introduced the Autumn Update 2019 at its annual resco.next conference in Rome.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191024005635/en/
Innovation delivered - Resco (Photo: Business Wire)
The release stands among Resco’s most significant, as it marks a year since the company officially began the expansion of its product portfolio with Resco Inspections, followed by Resco Routes. It delivers major new capabilities to both, as well as to the company’s Mobile Business Apps Platform.
“Our Autumn Update further strengthens Resco’s commitment to innovation that fosters business productivity. It also brings a number of features that extend Resco products to smartwatches,” confirmed Miro Pomsar, CEO at Resco.
More details in a fraction of time
With new Resco Inspections features like Tagged image and Reusable answers, field teams can complete inspections faster and provide more details with context to the back office. Ultimately, helping to speed up any issue resolution and boosting client satisfaction and loyalty.
Importantly, the solution is also coming to smartwatches as part of the Autumn Update. Field professionals can now complete inspection forms from their wrist, utilizing voice control for an entirely hands-free experience.
More information on Resco Inspections Autumn Update 2019 available here.
Handling unexpected situations
The upgraded Location Monitor in Resco Routes enables users to take the guesswork out of planning and effectively manage unforeseen events. Details such as an unlimited number of tracked staff members, real-time travel direction & speed, time of the last stop, and progress through the day, provide the backbone for truly informed decisions.
More information on Resco Routes Autumn Update 2019 available here.
Let the AI do the work
Resco’s Mobile Business Apps Platform has been extended with functionality that improves the efficiency of both mobile users and system administrators.
The all-new AI image recognition is available across all Resco-based app. Mobile users can now utilize image recognition instead of search or barcode scanning. More complex scenarios are also possible when utilizing image recognition in form rules.
Furthermore, when using Resco Cloud as a backend, administrators can create new fields and entities on the system directly from Woodford – no need to switch between applications. And with new project item categories, they can bring structure and clarity even to complex mobile projects.
More information on Resco’s Mobile Business Apps Platform Autumn Update 2019 available here.
Industry Watch for deeper business insights
At resco.next the company also introduced its all-new Industry Watch initiative - a new concept of utilizing smartwatches to obtain more insights from staff outdoors and indoors. Making entire organizations smarter and more efficient.
“We are excited about this new venture and the road that lies ahead. In the following months, we’re going to continue our intensive research in the area of wearables. We would also like to engage our whole ecosystem into this initiative, including our partners.” Miro Pomsar explained.
More details regarding Resco’s new smartwatch initiative can be found here.
About Resco
Resco founded in 1999, is one of the global leaders in developing cross-platform mobile software solutions. The team of Resco professionals utilizes their knowledge to design products for corporate customers, developers, integrators, and end users. Today, Resco is utilized by 2,800+ corporate customers with more than 250,000 licensed users around the world. The cornerstone of Resco’s Mobile Business Apps Platform is the Woodford configuration and management tool, which together with the Resco mobile app form the base of all Resco products.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191024005635/en/
Contact information
Resco Media Relations
Robert Feldmar
+421 2 209 020 17
communications@resco.net
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom